Tovorafenib Clinical Trials

4 actively recruiting trials across 3 locations

Also known as: AMG-2112819, BIIB 024, BIIB-024, BIIB024, BSK1369 +12 more

Pipeline

Phase 2: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

Day One Biopharmaceuticals, Inc.2
Sabine Mueller, MD, PhD1
National Cancer Institute (NCI)1

Indications

Cancer4
Low-grade Glioma2
Pediatric Low-grade Glioma1
Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma1
Recurrent Craniopharyngioma1

Birmingham, Alabama2 trials

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Children's of Alabama

Phase 3

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

University of Alabama at Birmingham

Phase 2

San Francisco, California1 trial

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

UCSF Benioff Children's Hospital

Phase 2

Columbus, Ohio1 trial

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.